Disparities in heart failure and other cardiovascular diseases among women

Women's Health

Volumn 8, Issue 4, 2012, Pages 473-485

  McSweeney, Jean ^a   Pettey, Christina ^a   Lefler, Leanne L ^a   Heo, Seongkum ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

cardiovascular disease; gender differences; heart failure; treatment; women

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; NITRATE; SPIRONOLACTONE;

AGING; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; COMORBIDITY; DEFIBRILLATOR; DISEASE SEVERITY; FLUID RETENTION; HEALTH DISPARITY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MORTALITY; PATIENT ATTITUDE; PATIENT COMPLIANCE; REVIEW; SELF CARE; SEX DIFFERENCE; SOCIAL SUPPORT; SOCIOECONOMICS; SODIUM RESTRICTION; THORAX PAIN;

ADULT; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; HEALTHCARE DISPARITIES; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; RISK FACTORS; SEX DISTRIBUTION; UNITED STATES; WOMEN'S HEALTH;

EID: 84863570561     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.12.22     Document Type: Review

References (93)

1. Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics - 2012 update. Circulation 125, E12-E230 (2011).
2. Jarvie JL, Foody JM. Recognizing and improving health care disparities in the prevention of cardiovascular disease in women. Curr. Cardiol. Rep. 12(6), 488-496 (2010).
3. Regitz-Zagrosek V, Seeland U. Sex and gender differences in myocardial hypertrophy and heart failure. Wien. Med. Wochenschr. 161(5-6), 109-116 (2011).
4. Hebert K, Lopez B, Horswell R et al. The impact of a standardized disease management program on race/ethnicity and gender disparities in care and mortality. J. Health Care Poor Underserved 21(1), 264-276 (2010).
5. Galvao M, Kalman J, DeMarco T et al. Gender differences in in-hospital management and outcomes in patients with decompensated heart failure: Analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J. Card Fail. 12(2), 100-107 (2006). (Pubitemid 43340150)
6. Levy D, Kenchaiah S, Larson MG et al. Long-term trends in the incidence of and survival with heart failure. N. Engl. J. Med. 347(18), 1397-1402 (2002). (Pubitemid 35239711)
7. Riegel B, Moser D. Care of patients with chronic heart failure. In: CARDIAC Nursing; A Companion to Braunwald's Heart Disease. Saunders Elsevier, MO, USA, 930-950 (2008).
8. Hunt SA, Abraham WT, Chin MH et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for heart and lung transplantation. JACC 53(15), E1-E90 (2009).
9. Lindenfeld J, Albert NM, Boehmer JP et al. HFSA 2010 comprehensive heart failure practice guideline. J. Card. Fail. 16(6), E1-E194 (2010).
10. Jurgens CY, Hoke L, Byrnes J, Riegel B. Why do elders delay responding to heart failure symptoms? Nurs. Res. 58(4), 274-282 (2009).
11. Riegel B, Moser DK, Anker SD et al. State of the science: Promoting self-care in persons with heart failure: A scientific statement from the American Heart Association. Circulation 120(12), 1141-1163 (2009).
12. Kenchaiah S, Evans JC, Levy D et al. Obesity and the risk of heart failure. N. Engl. J. Med. 347(5), 305-313 (2002). (Pubitemid 34815352)
13. Shah RU, Klein L, Lloyd-Jones DM. Heart failure in women: Epidemiology, biology and treatment. Womens Health (Lond. Engl.) 5(5), 517-527 (2009).
14. Mosca L, Benjamin EJ, Berra K et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women - 2011 update: A guideline from the American Heart Association. Circulation 123(11), 1243-1262 (2011).
15. Nilsson PM, Theobald H, Journath G, Fritz T. Gender differences in risk factor control and treatment profile in diabetes: A study in 229 swedish primary health care centres. Scand. J. Prim. Health Care 22(1), 27-31 (2004). (Pubitemid 38477887)
16. Schmittdiel JA, Traylor A, Uratsu CS, Mangione CM, Ferrara A, Subramanian U. The association of patient-physician gender concordance with cardiovascular disease risk factor control and treatment in diabetes. J. Womens Health (Larchmt.) 18(12), 2065-2070 (2009).
17. Nakaya N, Mizuno K, Ohashi Y et al. Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: Analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study). Drugs Aging 28(9), 681-692 (2011).
18. Sanchez DR, Diez Roux AV, Michos ED et al. Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of atherosclerosis. Am. J. Cardiol. 107(1), 41-46 (2011).
19. Nugent L, Mehta PK, Bairey Merz CN. Gender and microvascular angina. J. Thromb. Thrombolysis 31(1), 37-46 (2011).
20. Greyson DL, Becu AR, Morgan SG. Sex, drugs and gender roles: Mapping the use of sex and gender based analysis in pharmaceutical policy research. Int. J. Equity Health 9(26), 1-8 (2010).
21. McSweeney JC, Cody M, O'Sullivan P, Elberson K, Moser DK, Garvin BJ. Women's early warning symptoms of acute myocardial infarction. Circulation 108(21), 2619-2623 (2003). (Pubitemid 37466801)
22. Duenas M, Ramirez C, Arana R, Failde I. Gender differences and determinants of health-related quality of life in coronary patients: A follow-up study. BMC Cardiovasc. Dis. 11(24), 1-11 (2011).
23. Perelman J, Mateus C, Fernandes A. Gender equity in treatment for cardiac heart disease in Portugal. Soc. Sci. Med. 71(1), 25-29 (2010).
24. Tavris D, Shoaibi A, Chen AY, Uchida T, Roe MT, Chen J. Gender differences in the treatment of non-ST-segment elevation myocardial infarction. Clin. Cardiol. 33(2), 99-103 (2010).
25. Bugiardini R, Estrada JL, Nikus K, Hall AS, Manfrini O. Gender bias in acute coronary syndromes. Curr. Vasc. Pharmacol. 8(2), 276-284 (2010).
26. Brannstrom J, Hamberg K, Molander L, Lovheim H, Gustafson Y. Gender disparities in the pharmacological treatment of cardiovascular disease and diabetes mellitus in the very old: An epidemiological, cross-sectional survey. Drugs Aging 28(12), 993-1005 (2011).
27. Xhyheri B, Bugiardini R. Diagnosis and treatment of heart disease: Are women different from men? Prog. Cardiovasc. Dis. 53(3), 227-236 (2010).
28. De Feo S, Tramarin R, Ambrosetti M et al. Gender differences in cardiac rehabilitation programs from the Italian survey on cardiac rehabilitation (ISYDE-2008). Int. J. Cardiol. doi:10.1016/j.ijcard.2011.04.011 (2011) (Epub ahead of print).
29. Vaccarino V, Lin ZQ, Kasl SV et al. Gender differences in recovery after coronary artery bypass surgery. JACC 41(2), 307-314 (2003). (Pubitemid 36092202)
30. Heran BS, Chen JMH, Ebrahim S et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Sys. Rev. 7, CD001800 (2011).
31. Ghanbari H, Machado C
32. Dungan J, Yucha C, Artinian NT. Hypertension as a risk factor. In: CARDIAC Nursing: A Companion to Braunwald's Heart Disease. Saunders Elsevier, MO, USA, 431-445 (2008).
33. Regitz-Zagrosek V, Brokat S, Tschope C. Role of gender in heart failure with normal left ventricular ejection fraction. Prog. Cardiovasc. Dis. 49(4), 241-251 (2007). (Pubitemid 44932176)
34. Bench T, Burkhoff D, O'Connell JB et al. Heart failure with normal ejection fraction: Consideration of mechanisms other than diastolic dysfunction. Curr. Heart Fail. Rep. 6(1), 57-64 (2009).
35. Lamendola C. Insulin resistance, diabetes, and cariovascular disease. In: CARDIAC Nursing: A Companion to Braunwald's Heart Disease. Saunders Elsevier, MO, USA, 463-484 (2008).
36. Giles TD. The patient with diabetes mellitus and heart failure: At-risk issues. Am. J. Med. 115(8 Suppl. 1), S107-S110 (2003).
37. Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: A systematic review and meta-Analysis of prospective cohort studies. Lancet 378(9799), 1297-1305 (2011).
38. Boheler KR, Volkova M, Morrell C et al. Sex- and age-dependent human transcriptome variability: Implications for chronic heart failure. Proc. Natl Acad. Sci. USA 100(5), 2754-2759 (2003). (Pubitemid 36297571)
39. Haddad GE, Saunders LJ, Crosby SD et al. Human cardiac-specific cDNA array for idiopathic dilated cardiomyopathy: Sex-related differences. Physiol. Genomics 33(2), 267-277 (2008). (Pubitemid 351629534)
40. Heidecker B, Lamirault G, Kasper EK et al. The gene-expression profile of patients with new-onset heart failure reveals important gender-specific differences. Eur. Heart J. 31(10), 1188-1196 (2010).
41. Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW. Preferences for quality of life or survival expressed by patients with heart failure. J. Heart Lung Transplant. 20(9), 1016-1024 (2001). (Pubitemid 32824149)
42. Simpson K, Jarvis B. Lisinopril: A review of its use in congestive heart failure. Drugs 59(5), 1149-1167 (2000). (Pubitemid 30339141)
43. McMurray J, Ostergren J, Pfeffer M et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: Baseline characteristics of patients in the Candesartan in Heart failure - Assessment of Reduction in Mortality and Morbidity (CHARM) programme. Eur. J. Heart Fail. 5(3), 261-270 (2003). (Pubitemid 37011854)
44. Hasselblad V, Gattis SW, Shah MR et al. Relation between dose of loop diuretics and outcomes in a heart failure population: Results of the ESCAPE trial. Eur. J. Heart Fail. 9(10), 1064-1069 (2007). (Pubitemid 47451811)
45. Ghali JK, Pina IL, Gottlieb SS, Deedwania PC, Wikstrand JC. Metoprolol CR/XL in female patients with heart failure: Analysis of the experience in Metoprolol Extended- Release Randomized Intervention Trial in Health Failure (MERIT-HF). Circulation 105(13), 1585-1591 (2002). (Pubitemid 34297637)
46. O'Connor CM, Fiuzat M, Swedberg K et al. Influence of global region on outcomes in heart failure β-blocker trials. JACC 58(9), 915-922 (2011).
47. Schade CP, Hannah KL, Rezek G, Brehm JG. ACE inhibitor use and mortality reduction: Do controlled trial results equal clinical practice? W. V. Med. J. 102(1), 304-306 (2006).
48. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med. 325(5), 293-302 (1991).
49. Shibata MC, Tsuyuki RT, Wiebe N. The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure: A systematic review. Int. J. Clin. Pract. 62(9), 1397-1402 (2008).
50. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-preserved trial. Lancet 362(9386), 777-781 (2003). (Pubitemid 37093918)
51. Massie BM, Carson PE, McMurray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med. 359(23), 2456-2467 (2008).
52. Hudson M, Rahme E, Behlouli H, Sheppard R, Pilote L. Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure - A population study. Eur. J. Heart Fail. 9(6-7), 602-609 (2007). (Pubitemid 46702819)
53. Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence supporting the role of diuretics in heart failure: A meta analysis of randomised controlled trials. Int. J. Cardiol. 82(2), 149-158 (2002). (Pubitemid 34164392)
54. Ezekowitz JA, Lee DS, Tu JV, Newman AM, McAlister FA. Comparison of one-year outcome (death and rehospitalization) in hospitalized heart failure patients with left ventricular ejection fraction >50% versus those with ejection fraction <50% Am. J. Cardiol. 102 1 79-83 2008
55. Melloni C, Berger JS, Wang TY et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ. Cardiovasc. Qual. Outcomes 3(2), 135-142 (2010).
56. Baumhakel M, Muller U, Bohm M. Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. Eur. J. Heart Fail. 11(3), 299-303 (2009).
57. Pina IL, Kokkinos P, Kao A et al. Baseline differences in the HF-ACTION trial by sex. Am. Heart J. 158(Suppl. 4), S16-S23 (2009).
58. Walsh MN, Yancy CW, Albert NM et al. Equitable improvement for women and men in the use of guideline-recommended therapies for heart failure: Findings from IMPROVE HF. J. Card. Fail. 16(12), 940-949 (2010).
59. de Groote P, Isnard R, Assyag P et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur. J. Heart Fail. 9(12), 1205-1211 (2007). (Pubitemid 350153640)
60. Ghali JK, Lindenfeld J. Sex differences in response to chronic heart failure therapies. Expert Rev. Cardiovasc. Ther. 6(4), 555-565 (2008).
61. Regitz-Zagrosek V, Lehmkuhl E. Heart failure and its treatment in women. Role of hypertension, diabetes, and estrogen. Herz 30(5), 356-367 (2005). (Pubitemid 41238953)
62. Zuern CS, Lindemann S, Gawaz M. Platelet function and response to aspirin: Gender-specific features and implications for female thrombotic risk and management. Semin. Thromb. Hemost. 35(3), 295-306 (2009).
63. Curtis LH, Al-Khatib SM, Shea AM, Hammill BG, Hernandez AF, Schulman KA. Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. JAMA 298(13), 1517-1524 (2007). (Pubitemid 47529385)
64. Hernandez AF, Fonarow GC, Liang L et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA 298(13), 1525-1532 (2007). (Pubitemid 47529386)
65. Alaeddini J, Wood MA, Amin MS, Ellenbogen KA. Gender disparity in the use of cardiac resynchronization therapy in the United States. Pacing Clin. Electrophysiol. 31(4), 468-472 (2008). (Pubitemid 351467626)
66. Russo AM, Day JD, Stolen K et al. Implantable cardioverter defibrillators: Do women fare worse than men? Gender comparison in the INTRINSIC RV trial. J. Cardiovasc. Electrophysiol. 20(9), 973-978 (2009).
67. Ghanbari H, Dalloul G, Hasan R et al. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: A meta-Analysis of randomized controlled trials. Arch. Intern. Med. 169(16), 1500-1506 (2009).
68. Moser DK, Doering LV, Chung ML. Vulnerabilities of patients recovering from an exacerbation of chronic heart failure. Am. Heart J. 150(5), 984 (2005).
69. Cameron J, Worrall-Carter L, Riegel B, Lo SK, Stewart S. Testing a model of patient characteristics, psychologic status, and cognitive function as predictors of self-care in persons with chronic heart failure. Heart Lung 38(5), 410-418 (2009).
70. Gary R. Self-care practices in women with diastolic heart failure. Heart Lung 35(1), 9-19 (2006). (Pubitemid 43106631)
71. Eastwood CA, Travis L, Morgenstern TT, Donaho EK. Weight and symptom diary for self-monitoring in heart failure clinic patients. J. Cardiovasc. Nurs. 22(5), 382-389 (2007).
72. Lennie TA, Worrall-Carter L, Hammash M et al. Relationship of heart failure patients' knowledge, perceived barriers, and attitudes regarding low-sodium diet recommendations to adherence. Prog. Cardiovasc. Nurs. 23(1), 6-11 (2008).
73. Buckle J, Sharkey P, Myriski P, Smout R, Horn S. Improving outcomes for patients hospitalized with CHF. Manag. Care Q. 10(2), 30-40 (2002).
74. Chung ML, Moser DK, Lennie TA et al. Gender differences in adherence to the sodium-restricted diet in patients with heart failure. J. Card. Fail. 12(8), 628-634 (2006). (Pubitemid 44540259)
75. Newby LK, LaPointe NM, Chen AY et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 113(2), 203-212 (2006).
76. Granger BB, Ekman I, Granger CB et al. Adherence to medication according to sex and age in the CHARM programme. Eur. J. Heart Fail. 11(11), 1092-1098 (2009).
77. Eagle KA, Kline-Rogers E, Goodman SG et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: An ongoing prospective, observational study. Am. J. Med. 117(2), 73-81 (2004). (Pubitemid 38953725)
78. Akincigil A, Bowblis JR, Levin C, Jan S, Patel M, Crystal S. Long-term adherence to evidence based secondary prevention therapies after acute myocardial infarction. J. Gen. Intern. Med. 23(2), 115-121 (2008). (Pubitemid 351222564)
79. Dunlay SM, Eveleth JM, Shah ND, McNallan SM, Roger VL. Medication adherence among community-dwelling patients with heart failure. Mayo Clin. Proc. 86(4), 273-281 (2011).
80. Esposito D, Bagchi AD, Verdier JM, Bencio DS, Kim MS. Medicaid beneficiaries with congestive heart failure: Association of medication adherence with healthcare use and costs. Am. J. Manag. Care 15(7), 437-445 (2009).
81. Dragomir A, Cote R, Roy L et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med. Care 48(5), 418-425 (2010).
82. West D, Lefler L, Franks A. Examining medication adherence in older women with coronary heart disease. J. Women Aging 22(3), 157-170 (2010).
83. Jessup M, Abraham WT, Casey DE et al. 2009 focused update: Accf/AHA guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119(14), 1977-2016 (2009).
84. Bosworth HB, Granger BB, Mendys P et al. Medication adherence: A call for action. Am. Heart J. 162(3), 412-424 (2011).
85. Patterson ME, Blalock SJ, Smith AJ, Murray MD. Associations between prescription copayment levels and β-blocker medication adherence in commercially insured heart failure patients 50 years and older. Clin. Ther. 33(5), 608-616 (2011).
86. De Smedt RH, Haaijer-Ruskamp FM, Groenier KH, van der Meer K, Jaarsma T. Perceived adverse drug events in heart failure: Patients' perception and related factors. J. Cardiovasc. Nurs. 26(3), 250-260 (2011).
87. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the council for high blood pressure research. Circulation 117(25), E510-E526 (2008).
88. Daugherty SL, Ho PM, Spertus JA et al. Association of early follow-up after acute myocardial infarction with higher rates of medication use. Arch. Intern. Med. 168(5), 485-491 (2008). (Pubitemid 351547211)
89. Shah RU, Winkleby MA, Van Horn L et al. Education, income, and incident heart failure in post-menopausal women: The women's health initiative hormone therapy trials. JACC 58(14), 1457-1464 (2011).
90. Schwarz KA, Elman CS. Identification of factors predictive of hospital readmissions for patients with heart failure. Heart Lung 32(2), 88-99 (2003). (Pubitemid 36529987)
91. Harkness K, Demers C, Heckman GA, McKelvie RS. Screening for cognitive deficits using the montreal cognitive assessment tool in outpatients =65 years of age with heart failure. Am. J. Cardiol. 107(8), 1203-1207 (2011).
92. Gaviria M, Pliskin N, Kney A. Cognitive impairment in patients with advanced heart failure and its implications on decision-making capacity. Congest. Heart Fail. 17(4), 175-179 (2011).
93. Cameron J, Worrall-Carter L, Page K, Riegel B, Lo SK, Stewart S. Does cognitive impairment predict poor self-care in patients with heart failure? Eur. J. Heart Fail. 12(5), 508-515 (2010).